Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
BLUEJAY DIAGNOSTICS INC (BJDX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$2.19-4.37%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BJDX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise at least $20 million in capital by end of 2027 | Bluejay aims to raise $20 million by end of 2027. | Improving | fails to raise at least $20 million by end of 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 3 supplied quarters. Management reported: “At June 30, 2026, Bluejay had approximately $9.6 million in cash and cash equivalents, compared with approximately $5.2 million at December 31, 2025.” “We ended the quarter with approximately $9.6 million in cash, and our current cash resources are estimated to fund operations through the second quarter of 2027.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk development-stage medical-device business, not an established earnings compounder. The long-term thesis is on watch: management has progressed the pivotal study and manufacturing plans, but the business remains loss-making and recent performance is weak.
The valuation evidence describes BJDX as cheap versus peers, with low confidence in that comparison. The snapshot gives little detail on what investors expect, so it is unclear how much optimism about Symphony IL-6 is already reflected.
Near term, the risk of another earnings miss is elevated after consecutive recent misses. Over the multi-year view, completed enrollment of 750 patients and manufacturing progress support movement toward regulatory submission, while cash resources were estimated to fund operations only through 2027-Q2 and management expects to raise more capital.
The central swing factor is whether clinical analysis, FDA 510(k) submission, and commercialization readiness progress as planned. Near-term results also depend on avoiding a guidance cut and on funding the remaining capital needs; weaker jobs data could weigh on cyclical healthcare names, while strong results and guidance from sector peers could support the backdrop.
For the next 1-3 years, BJDX remains an uncertain, funding-dependent development story with meaningful clinical and earnings risks, despite tangible progress on its pivotal study and manufacturing. The evidence is limited and low-confidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Expand manufacturing via agreement with Argonaut | A supporting condition in BLUEJAY DIAGNOSTICS INC's published investment case. The stated target is successful ramp of Symphony platform manufacturing by next 4 quarters. | Improving | manufacturing ramp with Argonaut fails or delays significantly | Qualitative milestone hit vs 4-quarter target Company completed a manufacturing site milestone in October 2026, reinforcing the Argonaut expansion objective. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage cash burn and operating losses near recent levels | The company is working to reduce cash losses but still spends more than it earns. | Broken | operating income or net income worsens beyond recent levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-32.00 → $-32.00 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-07-25 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-07-26 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-07-27 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-07-28 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-07-29 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-07-30 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-07-31 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-01 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-02 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-03 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-04 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-05 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-06 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-07 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-08 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-09 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-10 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-11 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-12 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-13 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-14 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-15 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-16 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-17 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-18 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-19 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-20 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-21 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-22 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-23 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-24 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-25 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-26 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-27 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-28 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-29 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-30 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-08-31 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-01 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-02 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-03 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-04 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-05 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-06 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-07 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-08 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-09 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-10 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-11 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-12 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-13 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-14 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-15 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-16 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-17 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-18 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-19 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-20 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-21 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-22 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-23 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-24 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-25 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-26 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-27 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-28 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-29 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-09-30 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-01 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-02 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-03 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-04 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-05 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-06 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-07 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-08 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-09 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-10 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-11 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-12 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-13 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-14 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-15 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-16 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-17 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-18 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-19 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-20 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-21 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-22 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-23 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-24 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-25 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-26 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-27 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-28 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-29 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-30 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-10-31 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-11-01 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-11-02 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-11-03 | $-32.00 | $18,478,000 | 1 / 1 |
| 2026-11-04 | $-32.00 | $18,478,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.